Clinical Trials
21 trialsNCT05101148 2026-05-20
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT04590235 2026-05-14
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT07102394 2026-05-08
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
NCT06300502 2026-04-22
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Phase 1 Enrolling by invitation
NCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT05363267 2026-01-13
NF-1, Nutraceutical Intervention
Masonic Cancer Center, University of Minnesota
Phase 1 Active not recruiting
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT06132165 2025-11-21
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT04730583 2025-02-21
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT06120036 2025-02-21
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT02700230 2024-09-27
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed
NCT05438290 2024-05-06
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT04495127 2023-04-26
Selumetinib Paediatric NF1 Japan Study
AstraZeneca
Phase 1 Completed
NCT02415153 2022-04-25
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03649165 2018-11-08
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
AstraZeneca
Phase 1 Completed
NCT00865644 2017-01-10
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
Phase 1 Completed
NCT00352599 2016-11-22
NF1
University of California, Los Angeles
Phase 1 Completed
NCT00053937 2015-04-30
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00352495 2014-02-13
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Children's Oncology Group
Phase 1 Completed